Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells
- PMID: 2033043
Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells
Abstract
Bovine vascular smooth muscle cells (SMC) were examined for production of plasminogen activator inhibitor-1 (PAI-1) which may play a key role in regulating the fibrinolytic system. Growth-arrested SMC released active PAI (101 arbitrary units (AU)/10(6) cells/24 h) and a latent form of PAI (880 AU/10(6) cells/24 h) into the conditioned medium (CM). The levels of PAI were significant since 880 AU of PAI could inhibit approximately 1 microgram of tissue plasminogen activator. The extracellular matrix of SMC also contained PAI activity; however, the level was 17-fold less than that observed in the CM. SMC-PAI was a rapid inhibitor of tissue plasminogen activator (kass greater than 10(7) M-1 S-1) and was identified as a 45-kDa protein immunologically related to endothelial cell PAI-1. PAI-1 comprised 20 and 30%, respectively, of the newly synthesized protein detected in the CM and extracellular matrix of SMC. The SMC growth modulators, platelet-derived growth factor and transforming growth factor-beta, induced PAI-1 activity and protein synthesis by 2- and 3-fold, respectively, in a dose- and time-dependent manner. The increases in PAI-1 activity and protein synthesis were ascribed to elevated levels of PAI-1 mRNA as judged by Northern blot analysis of total RNA prepared from control and platelet-derived growth factor- and transforming growth factor-beta-treated cells. Increases in PAI-1 mRNA levels were evident 1 h after growth factor treatment and were maximal after 4 h. PAI-1 mRNA levels were unaffected by cycloheximide treatment. The results indicate that SMC synthesize and release PAI-1 which could regulate the normal fibrinolytic environment of the arterial wall. During atherosclerosis or after vascular injury increases in platelet-derived or locally produced mitogens may stimulate further PAI-1 synthesis and generate a prothrombotic state.
Similar articles
-
Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo.Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):723-30. doi: 10.1161/01.atv.17.4.723. Arterioscler Thromb Vasc Biol. 1997. PMID: 9108786
-
T-cell lymphokines, interleukin-4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet-derived growth factor.Circ Res. 1995 Dec;77(6):1095-106. doi: 10.1161/01.res.77.6.1095. Circ Res. 1995. PMID: 7586221
-
Effect of thrombin, the thrombin receptor activation peptide, and other mitogens on vascular smooth muscle cell urokinase receptor mRNA levels.Blood. 1994 Dec 1;84(11):3700-8. Blood. 1994. PMID: 7949125
-
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha.J Biol Chem. 1989 Jun 25;264(18):10396-401. J Biol Chem. 1989. PMID: 2499579
-
Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.J Cell Physiol. 1991 Oct;149(1):34-43. doi: 10.1002/jcp.1041490106. J Cell Physiol. 1991. PMID: 1834680
Cited by
-
Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms.Am J Pathol. 1998 Mar;152(3):703-10. Am J Pathol. 1998. PMID: 9502412 Free PMC article.
-
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.Cancer Chemother Pharmacol. 2011 May;67(5):1119-28. doi: 10.1007/s00280-010-1405-y. Epub 2010 Jul 31. Cancer Chemother Pharmacol. 2011. PMID: 20676674 Free PMC article. Clinical Trial.
-
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.Vasc Health Risk Manag. 2014 Apr 3;10:177-88. doi: 10.2147/VHRM.S36045. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 24729713 Free PMC article. Review.
-
Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?J Thromb Thrombolysis. 1999 Jun;7(3):277-85. doi: 10.1023/a:1008983110941. J Thromb Thrombolysis. 1999. PMID: 10375389 Review.
-
TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2102-2113. doi: 10.1161/ATVBAHA.117.309401. Epub 2017 Jul 20. Arterioscler Thromb Vasc Biol. 2017. PMID: 28729364 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous